Safety Study of ExAblate for the Treatment of Uterine Fibroids

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

121 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this Phase IV study is to evaluate the safety of the ExAblate treatment of uterine fibroids using the enhanced sonication techniques, based on the current commercially-approved treatment guidelines. Treatment may include up to 100% of individual fibroid volume, within established serosal and sacral treatment margins.

The Enhanced sonication is one of the various sonication modes that may lead to increased thermal dose volume of each sonication without additional safety risks. This is an additional treatment tool available in the ExAblate system for the treatment of uterine fibroids.

The safety profile of the Enhanced Sonication was investigated under an FDA-regulated IDE study. FDA granted approval of Enhanced Sonication with the requirement to perform a post-approval study to collect additional safety data when treating up to 100% of individual fibroid volume.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

NCT05386615

Uterine Fibroid

RECRUITING

Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids

NCT02386137

Uterine Fibroid

COMPLETED NA

Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future

NCT00180739

Uterine Fibroids Pregnancy

WITHDRAWN PHASE4

Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound

NCT02633254

Uterine Fibroid

TERMINATED NA

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174

Menorrhagia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ExAblate treatment

Group Type OTHER

ExAblate

Intervention Type DEVICE

Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ExAblate

Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women age 18 or older
* Symptomatic uterine fibroids, defined as those resulting in scores of 21 or higher, based on patient responses to questions 1-8 of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL)
* Women who have given written informed consent
* Women who are able and willing to attend all study visits.
* Patient is pre or peri-menopausal (within 12 months of last menstrual period).
* Patient should be family complete.
* Able to communicate sensations during the ExAblate procedure.
* Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
* Fibroids(s) clearly visible on non-contrast MRI.
* Fibroid enhances on MR contrast imaging.

Exclusion Criteria

* Women who are pregnant, as confirmed by serum/urine test at time of screening, or urine pregnancy test on the day of treatment.
* Patients who are breast-feeding.
* Patients with active pelvic inflammatory disease (PID).
* Patients with active local or systemic infection.
* Patients experiencing chronic leg or lower back pain within the last 6 months.
* Contraindication for MRI Scan:

* Severe claustrophobia that would prevent completion of procedure in the MR unit
* Weight greater than 250 lbs (113Kg)
* Implanted ferromagnetic materials and/or devices contraindicated for MR scan
* Known intolerance to MRI contrast agent (e.g. Gadolinium or Magnevist)
* Any other contraindication for MRI Scan
* Extensive abdominal scarring in the beam path (that cannot be avoided by redirection of the beam).
* Dermoid cyst of the ovary anywhere in the treatment path.
* Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.
* Intrauterine device (IUD) anywhere in the treatment path.
* Undiagnosed vaginal bleeding.
* Pedunculated fibroids.
* Uterine size \>24 weeks.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No